Radiopharmaceuticals Market Report Analysis With Industry Share Published by Leading Research Firm

Radiopharmaceuticals Market: Introduction


radiopharmaceuticals market


Increase in Application of Radiopharmaceuticals Compounds as Imaging Agents in Non-oncology Conditions to Drive Market


Clinical applications of positron emission tomography/computed tomography (PET-CT) with the glucose analogue 2-[fluorine 18] fluoro-2-deoxy-D-glucose (FDG) radiopharmaceuticals compound are spreading beyond oncology. Apart from its high usage in clinical oncology, FDG PET-CT is widely used in various non-oncologic specialties such as cardiology, neurology, and cognitive neuroscience. In several centers, cardiac FDG PET is becoming the gold standard for assessment of myocardial viability. In patients with cardiac sarcoidosis, FDG PET has proven useful as a follow-up tool for disease monitoring. This is likely to drive the global market.


Request a PDF Brochure -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=213


Technetium-99m to Dominate Global Market


The global radiopharmaceuticals market has been segmented based on compound, indication, system, and end-user. In terms of compound, the global radiopharmaceuticals market has been classified into fluorine-18 derivatives, tc-99, Lu-177, Ga-68, Zr-89, 11C-choline, 14C-urea, and others. The tc-99 segment is anticipated to account for major share of the global market by 2031 due to lower price and easy production process. Moreover, the compound is suitable for imaging the thyroid, lacrimal glands, vascular perfusion, pulmonary perfusion, bones, myocardial, etc.


Oncology to be Key Indication


Based on indication, the global radiopharmaceuticals market has been categorized into oncology, neurology, cardiology, and others. The oncology segment is expected to expand at a high CAGR during the forecast period due to increase in demand for radiopharmaceuticals agents for better treatment access in oncology across the globe.


Request for Custom Research -

https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=213


Hospitals to be Major End User


In terms of end-user, the global radiopharmaceuticals market has been divided into hospitals, diagnostic labs, and others. The hospitals segment is expected to expand at a high CAGR during the forecast period due to increase in demand for installation of new PET-CT machines in the upcoming hospital projects across the globe.


North America to Lead Global Market


The global radiopharmaceuticals market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World. North America dominated the global radiopharmaceuticals market in 2020, followed by Europe. North America accounted for major share of the global radiopharmaceuticals market in 2020, due to rise in installations of PET-CT scanner device and increase in demand for disease risk assessment services for oncology treatment. The radiopharmaceuticals market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2031. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are projected to drive the radiopharmaceuticals market in the region.


Buy Radiopharmaceuticals Market Report -

https://www.transparencymarketresearch.com/checkout.php?rep_id=213&ltype=S


Competition Landscape


The report also presents profiles of leading players in the global radiopharmaceuticals market. These include Siemens Healthineers, GE Healthcare, Advanced Accelerator Applications (a Novartis AG Company), Jubilant Pharma Limited, Bayer AG, ITM Isotopen Technologien München AG, Telix Pharmaceuticals, Lantheus Holdings, Inc., Eli Lilly and Company, Nihon Medi-Physics, and Avanos Medical, Inc.


Leading companies in the global radiopharmaceuticals market focus on strengthening the distribution network and expanding product range & applications to gain market share. For instance, in January 2018, Advanced Accelerator Applications received the U.S. FDA approval for Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors.


More Trending Reports by Transparency Market Research –


Pharmaceutical Excipients Market:

https://www.prnewswire.co.uk/news-releases/global-pharmaceutical-excipients-market-to-expand-as-fda-ramps-up-approval-of-new-drug-classes-tmr-817327344.html


Vesical Drainage Catheters Market:

https://www.biospace.com/article/vesical-drainage-catheters-market-surge-in-the-geriatric-population-is-anticipated-to-drive-the-market/


About Us


Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.


Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.


Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website:https://www.transparencymarketresearch.com/

4.7 Star App Store Review!
Cpl.dev***uke
The Communities are great you rarely see anyone get in to an argument :)
king***ing
Love Love LOVE
Download

Select Collections